News Feature Channel: Clinical Trials

Roswell Park Researchers to Discuss Recent Discoveries and Critical Issues in Oncology at AACR 2025

Roswell Park Comprehensive Cancer Center — Thu, 17 Apr 2025 20:55:38 EST

Researchers from Roswell Park will report their latest findings to colleagues from around the world at the 2025 annual meeting of the American Association for Cancer Research (AACR) in Chicago, Illinois, April 25-30.

Monell Center Study Identifies GLP-1 Therapies as a Possible Treatment for Rare Genetic Disorder Bardet-Biedl Syndrome

Monell Chemical Senses Center — Thu, 17 Apr 2025 20:45:00 EST

Monell Center investigators identified that GLP-1R agonists, a class of drugs currently used to treat type-2 diabetes and obesity, as a promising therapeutic for managing the metabolic complications associated with Bardet-Biedl Syndrome (BBS), a rare genetic disorder characterized by early-onset obesity, compulsive eating, and cognitive impairments. They used a genetically engineered mouse model of BBS that displayed the hallmark features of the condition.

Wesley Sundquist Named to TIME's Annual TIME100 List of the 100 Most Influential People in the World

University of Utah Health — Thu, 17 Apr 2025 13:05:59 EST

Research in the Sundquist lab laid the foundations for the development of lenacapavir, a drug that prevents HIV infection with 99.9% to 100% efficacy and could dramatically lower infection rates worldwide.

New Drug Targets Bone Disease by Blocking the Wnt Signaling Pathway

Chinese Academy of Sciences — Wed, 16 Apr 2025 08:10:47 EST

Sclerosteosis is a rare genetic disorder that causes excessive bone growth, leading to life-altering complications, including hearing loss and facial paralysis. In a promising new breakthrough, researchers have identified a drug called LGK974, which targets the Wnt signaling pathway by inhibiting the enzyme Porcupine.

Largest Genome-Wide Association Study Uncovers New Drug Targets and Potential Therapies for Osteoarthritis

University of Maryland School of Medicine — Tue, 15 Apr 2025 18:10:19 EST

Largest Genome-Wide Association Study Uncovers New Drug Targets and Potential Therapies for Osteoarthritis

Combination Therapy Shows Promise for Hard-to-Treat Pancreatic Cancer

American Society for Biochemistry and Molecular Biology (ASBMB) — Tue, 15 Apr 2025 17:30:33 EST

Mouse study reveals synergistic effects from combining drugs that target key epigenetic and DNA repair proteins

Cell Therapy for Brain Tumors: Foundation Hosts Focused Ultrasound Roundtable

Focused Ultrasound Foundation — Tue, 15 Apr 2025 09:00:45 EST

Cell Therapy for Brain Tumors: Foundation Hosts Focused Ultrasound Roundtable

Moffitt-Led International Study Finds New Drug Delivery System Effective Against Rare Eye Cancer

Moffitt Cancer Center — Thu, 10 Apr 2025 20:20:06 EST

A multi-institutional study led by Moffitt Cancer Center found that percutaneous hepatic perfusion using a melphalan hepatic delivery system may help patients with a rare eye cancer that has spread to their liver. This disease, known as metastatic uveal melanoma, is traditionally very hard to treat and usually has poor outcomes.

Crystal L. Mackall, MD, FAACR, Recognized with the 2025 AACR-Cancer Research Institute Lloyd J. Old Award in Cancer Immunology

Cancer Research Institute — Thu, 10 Apr 2025 10:50:46 EST

The American Association for Cancer Research (AACR)-Cancer Research Institute (CRI) Lloyd J. Old Award in Cancer Immunology will be presented to Crystal L. Mackall, MD, Fellow of the AACR Academy, during the AACR Annual Meeting 2025, to be held April 25-30 at the McCormick Place Convention Center in Chicago, Illinois.

Clinical Trial Opens for Patients with High-Grade Neuroendocrine Cancer

Sylvester Comprehensive Cancer Center — Wed, 09 Apr 2025 20:50:37 EST

A clinical trial for patients with high-grade neuroendocrine tumors is now open for enrollment at Sylvester Comprehensive Cancer Center. The new trial will test the novel combination of immunotherapy paired with a tumor-busting virus.

Stroke Patients Discharged from Hospital Sooner when Administered Revalesio's RNS60; New Statistically Significant Finding from Revalesio's Phase 2 Clinical Trial

Revalesio Corporation — Wed, 09 Apr 2025 09:05:08 EST

Results presented during oral presentation at the American Academy of Neurology 2025 Annual Meeting

UC San Diego Health Named Region's Only Level 4 Adult Epilepsy Center

UC San Diego Health — Tue, 08 Apr 2025 20:25:23 EST

HSS Studies Identify Potential Profile and Treatment Options for Mild Traumatic Brain Injury

Hospital for Special Surgery — Tue, 08 Apr 2025 18:00:15 EST

Two studies by scientists at Hospital for Special Surgery (HSS) offer possible insights into treating mild traumatic brain injury (mTBI), including a potential blood biomarker for injury assessment that could shed light on the role of inflammation, and evidence supporting the use of amitriptyline, historically used as an anti-depressant, but now commonly used for migraine relief, to speed recovery. The research team shared their results today at the American Academy of Neurology 2025 annual meeting.

Powerful New Tool Promises Major Advances in Cancer Treatment

University of South Australia — Tue, 08 Apr 2025 12:00:57 EST

New Australian technology is set to transform the way that gastrointestinal cancers are detected and treated with precise, minimally invasive surgery.Backed by the Federal Government's...

Setback in Gene Therapy for Duchenne Muscular Dystrophy as Immune System Emerges as Key Barrier

University of Portsmouth — Tue, 08 Apr 2025 03:45:15 EST

A new paper, published in Gene Therapy, raises serious concerns about the effectiveness of gene therapy for Duchenne muscular dystrophy (DMD), after the treatment failed to show significant benefit in a large-scale clinical trial.

Clinical Study Shows Modulation of Ki-67 Markers by those taking Avmacol(r) in Former Smokers at High-risk for Lung Cancer

Nutramax Laboratories — Mon, 07 Apr 2025 21:55:03 EST

Clinical Study Shows Modulation of Ki-67 Markers by those taking Avmacol(r) in Former Smokers at High-risk for Lung Cancer

Test Predicts Which Patients with Prostate Cancer Are Most Likely to Develop Long-Term Side Effects From Radiation Therapy

University of California, Los Angeles (UCLA), Health Sciences — Mon, 07 Apr 2025 11:20:58 EST

The test, called PROSTOX, is the first of its kind to use microRNAs to predict toxicity from cancer therapy. It could help prevent the burden of long-term complications by identifying patients most at risk before treatment even begins.

Hospitalization Offers Chance to Begin Treatment for Patients With Opioid Use Disorder

Cedars-Sinai — Mon, 07 Apr 2025 11:10:08 EST

Patients hospitalized with opioid use disorders who receive addiction consultation services are significantly more likely to start medication treatment and access follow-up care when compared with patients who receive standard or usual care, a study co-led by Cedars-Sinai investigators found.

Measles and Vaccines: Recording of Recent Media Briefing

Johns Hopkins Bloomberg School of Public Health — Sun, 06 Apr 2025 14:10:58 EST

Researchers Identify "Master Regulator" Gene That Could Lead to More Effective Treatment for Patients with Ovarian Cancer

University of Maryland School of Medicine — Thu, 03 Apr 2025 09:15:47 EST

In a study co-led by the University of Maryland School of Medicine (UMSOM), researchers have identified a "master regulator" gene, ZNFX1, that may act as a biomarker to help guide treatment in future clinical trials involving patients with therapy-resistant ovarian cancer, according to a study recently published in Cancer Research.